Background: Fluoroquinolone agents, such as enrofloxacin and marbofloxacin, are commonly used for pseudomonal infection in veterinary medicine. However, the rate of resistance to fluoroquinolones is rapidly increasing, according to multiple studies in various countries. Point mutations in the quinolone resistance-determining region (QRDR) are closely related to the increased fluoroquinolone resistance of Pseudomonas aeruginosa. The aim of this study was to investigate current antimicrobial susceptibility and fluoroquinolone resistance in P. aeruginosa strains isolated from dogs. The presence of point mutations in the QRDR was confirmed by gyrA and parC polymerase chain reaction and nucleotide sequencing analysis.
Results: A total of 84 nonduplicated P. aeruginosa strains were obtained from 228 healthy dogs (healthy group) and 260 dogs with clinical signs (infected group). Among these isolates, 38 strains from the healthy group were detected in several sample types, whereas 46 strains from the infected group were obtained mostly from dogs’ ears with otitis externa (41/260, 15.8%). All strains were resistant to nalidixic acid, while some were also resistant to enrofloxacin (23/84, 27.4%), marbofloxacin (17/84, 20.2%), levofloxacin (12/84, 14.3%), or ciprofloxacin (11/84, 13.1%). Enrofloxacin resistance was significantly higher in strains from the infected group than in those from the healthy group (p<0.05). Among the 23 fluoroquinolone-resistant strains, 8 and 4 different mutations were detected in the gyrA and parC genes, respectively. Mutations in gyrA were significantly common in the infected group (p<0.05). Hotspots for the gyrA and parC mutations were Thr83 (34.8%, 8/23) and Pro116 (91.3%, 21/23), respectively. Double and triple mutations were also found in 5 of the strains.
Conclusion: Novel mutations in the gyrA and parC genes were first found in P. aeruginosa isolated from companion dogs in South Korea. These findings suggest that it is important to encourage prudent use of fluoroquinolone antibiotics in canine pseudomonal infection treatment.
Figure 1
Loading...
Posted 26 Mar, 2020
On 25 Mar, 2020
On 24 Mar, 2020
On 23 Mar, 2020
On 23 Mar, 2020
On 18 Mar, 2020
On 18 Mar, 2020
On 10 Mar, 2020
On 26 Feb, 2020
On 25 Feb, 2020
On 25 Feb, 2020
On 30 Jan, 2020
Received 20 Jan, 2020
Received 20 Jan, 2020
On 17 Jan, 2020
Invitations sent on 17 Jan, 2020
On 17 Jan, 2020
On 17 Jan, 2020
On 16 Jan, 2020
On 16 Jan, 2020
On 18 Dec, 2019
Received 10 Dec, 2019
On 29 Nov, 2019
Received 20 Nov, 2019
On 17 Nov, 2019
Received 09 Sep, 2019
On 02 Sep, 2019
Invitations sent on 01 Sep, 2019
On 20 Aug, 2019
On 16 Aug, 2019
On 16 Aug, 2019
On 11 Aug, 2019
Posted 26 Mar, 2020
On 25 Mar, 2020
On 24 Mar, 2020
On 23 Mar, 2020
On 23 Mar, 2020
On 18 Mar, 2020
On 18 Mar, 2020
On 10 Mar, 2020
On 26 Feb, 2020
On 25 Feb, 2020
On 25 Feb, 2020
On 30 Jan, 2020
Received 20 Jan, 2020
Received 20 Jan, 2020
On 17 Jan, 2020
Invitations sent on 17 Jan, 2020
On 17 Jan, 2020
On 17 Jan, 2020
On 16 Jan, 2020
On 16 Jan, 2020
On 18 Dec, 2019
Received 10 Dec, 2019
On 29 Nov, 2019
Received 20 Nov, 2019
On 17 Nov, 2019
Received 09 Sep, 2019
On 02 Sep, 2019
Invitations sent on 01 Sep, 2019
On 20 Aug, 2019
On 16 Aug, 2019
On 16 Aug, 2019
On 11 Aug, 2019
Background: Fluoroquinolone agents, such as enrofloxacin and marbofloxacin, are commonly used for pseudomonal infection in veterinary medicine. However, the rate of resistance to fluoroquinolones is rapidly increasing, according to multiple studies in various countries. Point mutations in the quinolone resistance-determining region (QRDR) are closely related to the increased fluoroquinolone resistance of Pseudomonas aeruginosa. The aim of this study was to investigate current antimicrobial susceptibility and fluoroquinolone resistance in P. aeruginosa strains isolated from dogs. The presence of point mutations in the QRDR was confirmed by gyrA and parC polymerase chain reaction and nucleotide sequencing analysis.
Results: A total of 84 nonduplicated P. aeruginosa strains were obtained from 228 healthy dogs (healthy group) and 260 dogs with clinical signs (infected group). Among these isolates, 38 strains from the healthy group were detected in several sample types, whereas 46 strains from the infected group were obtained mostly from dogs’ ears with otitis externa (41/260, 15.8%). All strains were resistant to nalidixic acid, while some were also resistant to enrofloxacin (23/84, 27.4%), marbofloxacin (17/84, 20.2%), levofloxacin (12/84, 14.3%), or ciprofloxacin (11/84, 13.1%). Enrofloxacin resistance was significantly higher in strains from the infected group than in those from the healthy group (p<0.05). Among the 23 fluoroquinolone-resistant strains, 8 and 4 different mutations were detected in the gyrA and parC genes, respectively. Mutations in gyrA were significantly common in the infected group (p<0.05). Hotspots for the gyrA and parC mutations were Thr83 (34.8%, 8/23) and Pro116 (91.3%, 21/23), respectively. Double and triple mutations were also found in 5 of the strains.
Conclusion: Novel mutations in the gyrA and parC genes were first found in P. aeruginosa isolated from companion dogs in South Korea. These findings suggest that it is important to encourage prudent use of fluoroquinolone antibiotics in canine pseudomonal infection treatment.
Figure 1
Loading...